ArticleFrontiers in immunology2023
Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: first reported case.
Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 13 citations in OpenAlex.
- Elranatamab: A novel B-cell maturation T-cell engager.Human vaccines & immunotherapeutics · 2026Review
- The Effectiveness of Elranatamab in the Management of Refractory Multiple Myeloma with Central Nervous System Involvement.Internal medicine (Tokyo, Japan) · 2026Article
- Durable CNS remission with elranatamab and intrathecal therapy in relapsed/refractory multiple myeloma.Annals of hematology · 2026Article
- Delayed-onset parkinsonism possibly associated with elranatamab treatment for relapsed/refractory multiple myeloma: a case report of a poorly characterized neurological event.Annals of hematology · 2026Article
- Central nervous system multiple myeloma: An update for 2026.Annals of hematology · 2026Review
- Central nervous system involvement in plasma cell neoplasms: a rare presentation illustrated by three cases.International journal of hematology · 2026Article
- Case Report: Central nervous system relapse treated with elranatamab after prior BCMA and GPRC5D directed therapies in relapsed/refractory multiple myeloma.Frontiers in oncology · 2026Article
- Teclistamab for ultrahigh-risk multiple myeloma with isolated central nervous system relapse.Archives of medical science : AMS · 2026Article
- Bispecific antibody therapy in CNS myeloma: Early evidence from a multicentre cohort.British journal of haematology · 2025Article
- Central nervous system myeloma: Pathogenesis, diagnostic challenges, and practical management strategies.HemaSphere · 2025Review
- Real-world FDA database analysis unveiling cardiovascular adverse events associated with bispecific T cell engagers in multip myeloma.Scientific reports · 2025Article
- A Case Report Supporting the Use of Teclistamab in Multiple Myeloma With CNS Involvement.Case reports in hematology · 2025Article
- Isolated relapse of multiple myeloma in the central nervous system post autologous hematopoietic stem cell transplantation: a case report and literature review.Frontiers in oncology · 2025Article
- Article
- Isolated central nervous system (CNS) relapse of multiple myeloma 11 years after autologous stem cell transplantation: a case report.AME case reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Central nervous system (CNS) involvement in multiple myeloma (MM) is a rare and challenging complication associated with poor prognosis and limited treatment options. Emerging T-cell directing therapies, such as bispecific antibodies (bsAbs) and chimeric antigen receptor T cells (CAR-T), have shown remarkable success in treating MM, but their efficacy in CNS involvement remains unclear. Elranatamab, a humanized bispecific antibody targeting B-cell maturation antigen (BCMA) and CD3-expressing T cells, has demonstrated promising results in relapsed refractory MM. However, its efficacy in treating CNS-MM has not been reported. We present a case of a 37-year-old male MM patient with CNS involvement who has been successfully treated with Elranatamab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.